High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X L in chronic myeloid leukemia

Leukemia

Volumn 30, Issue 6, 2016, Pages 1273-1281

  Lucas, C M ^a   Milani, M ^a   Butterworth, M ^a   Carmell, N ^a   Scott, L J ^a   Clark, R E ^a   Cohen, G M ^a   Varadarajan, S ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; A 1210477; A 1331852; ANTILEUKEMIC AGENT; BH3 PROTEIN; BIM PROTEIN; BIOLOGICAL MARKER; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; DASATINIB; IMATINIB; NILOTINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PUMA PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VENETOCLAX; A-1331852; AUTOANTIGEN; BENZOTHIAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN BCL X;

ADULT; ANTIAPOPTOTIC PHENOTYPE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FOLLOW UP; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RNA INTERFERENCE; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; FEMALE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; APOPTOSIS; AUTOANTIGENS; BCL-X PROTEIN; BENZOTHIAZOLES; BIOMARKERS, TUMOR; CELL LINE, TUMOR; FEMALE; HUMANS; ISOQUINOLINES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84961221160     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.42     Document Type: Article

References (46)

1. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-214.
2. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008; 22: 1963-1966.
3. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
4. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
5. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011; 117: 6660-6668.
6. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62.
7. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten J-P, Lundin M et al. MYCdependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101: 793-805.
8. Lucas CM, Harris RJ, Giannoudis A, Clark RE. c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica 2015; 100: e179-e182.
9. Kim H, Rafiuddin-Shah M, Tu H-C, Jeffers JR, Zambetti GP, Hsieh JJ-D et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348-1358.
10. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
11. Ku B, Liang C, Jung JU, Oh B-H. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res 2011; 21: 627-641.
12. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000; 3: 299-305.
13. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000; 191: 977-984.
14. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and-independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000; 20: 1179-1186.
15. Salomoni P, Condorelli F, Sweeney SM, Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 2000; 96: 676-684.
16. Korfi K, Mandal A, Furney SJ, Wiseman D, Somervaille TCP, Marais R. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. Ann Oncol 2015; 26: 1180-1187.
17. Mak DH, Wang R-Y, Schober WD, Konopleva M, Cortes J, Kantarjian H et al. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2012; 26: 788-794.
18. Ko TK, Chuah CTH, Huang JWJ, Ng K-P, Ong ST. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget 2014; 5: 9033-9038.
19. Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ et al. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 2013; 27: 1996-2005.
20. Song T, Chai G, Liu Y, Xie M, Chen Q, Yu X et al. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition. Eur J Pharm Sci 2015; 70: 64-71.
21. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
22. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
23. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015; 7: 279ra40.
24. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.
25. Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013; 61: 156-164.
26. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M, Dyer MJS et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413.
27. Lucas CM, Harris RJ, Holcroft AK, Scott LJ, Carmell N, McDonald E et al. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia 2015; 29: 1514-1523.
28. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015; 160: 977-989.
29. Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013; 121: 2739-2742.
30. O'Brien S, Hedgley C, Foroni L, Apperley J, Osborne W, Zwingers T et al. SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia-2 year follow up. Accepted for the European Haematology Association Annual Meeting: Vienna, June 2015 (oral presentation).
31. Hughes TP, Larson RA, Kim D-W, Issaragrisil S, le Coutre PD, Lobo C et al. Efficacy and safety of nilotinib (NIL) vs. imatinib (IM) in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP): 6-year follow-up of ENESTnd. Accepted for the European Haematology Association Annual Meeting: Vienna, Austria, June 2015 (poster presentation).
32. Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Eur J Haematol 2004; 72: 231-238.
33. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169-3175.
34. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998; 16: 1383-1390.
35. Bai H, Chen K, Gao Y-X, Arzigian M, Xie Y-L, Malcosky C et al. Bcl-xL enhances single-cell survival and expansion of human embryonic stem cells without affecting self-renewal. Stem Cell Res 2012; 8: 26-37.
36. Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A et al. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death Differ 2014; 21: 1877-1888.
37. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
38. Vogler M, Hamali HA, Sun X-M, Bampton ETW, Dinsdale D, Snowden RT et al. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011; 117: 7145-7154.
39. Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606-614.
40. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092-5100.
41. Huang LP, Adelson ME, Mordechai E, Trama JP. CIP2A expression is elevated in cervical cancer. Cancer Biomark 2010; 8: 309-317.
42. Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E, Trama JP. CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med 2012; 1: 76-81.
43. Teng H-W, Yang S-H, Lin J-K, Chen W-S, Lin T-C, Jiang J-K et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012; 16: 1037-1047.
44. He H, Wu G, Li W, Cao Y, Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 2012; 21: 143-149.
45. Dong Q-Z, Wang Y, Dong X-J, Li Z-X, Tang Z-P, Cui Q-Z et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18: 857-865.
46. De P, Carlson J, Leyland-Jones B, Dey N. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. Oncotarget 2014; 5: 4581-4602.